FACTORS INFLUENCING ADRENOCORTICAL SUPPRESSION DURING LONG-TERM TRIAMCINOLONE ACETONIDE THERAPY IN ASTHMA

  • 1 January 1980
    • journal article
    • research article
    • Vol. 44  (3) , 174-176
Abstract
The causes for an abnormal 5 h tetracosactrin test in 14 out of 75 patients (18.5% of the entire group), treated continuously with triamcinolone acetonide long-term (mean 3.2 yr) for asthma or related syndromes, were investigated. The average daily dosage, duration of treatment and age of the patients were analyzed. Statistical analysis indicated that the risk of adrenocortical suppression was increased by the patient''s age and the average daily dose of the drug, but not by the duration of therapy. Patients under the age of 50, receiving less than 2.2 mg triamcinolone acetonide daily, apparently only rarely develop adrenocortical functional impairment.